Cargando…

Influence of rapid COVID-19 vaccine development on vaccine hesitancy

INTRODUCTION: In the race to deploy vaccines to prevent COVID-19, there is a need to understand factors influencing vaccine hesitancy. Secondary risk theory is a useful framework to explain this, accounting for concerns about vaccine efficacy and safety. METHODS: During the first week of July, 2020,...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenthal, Sonny, Cummings, Christopher L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590511/
https://www.ncbi.nlm.nih.gov/pubmed/34802786
http://dx.doi.org/10.1016/j.vaccine.2021.11.014
_version_ 1784598985593323520
author Rosenthal, Sonny
Cummings, Christopher L.
author_facet Rosenthal, Sonny
Cummings, Christopher L.
author_sort Rosenthal, Sonny
collection PubMed
description INTRODUCTION: In the race to deploy vaccines to prevent COVID-19, there is a need to understand factors influencing vaccine hesitancy. Secondary risk theory is a useful framework to explain this, accounting for concerns about vaccine efficacy and safety. METHODS: During the first week of July, 2020, participants (N = 216) evaluated one of three different hypothetical vaccine scenarios describing an FDA-approved vaccine becoming available “next week,” “in one year,” or “in two years.” Dependent variables were perceived vaccine efficacy, self-efficacy, perceived vaccine risk, and vaccination willingness. Covariates included vaccine conspiracy beliefs, science pessimism, media dependency, and perceived COVID-19 risk. Data analysis employed multiple analysis of covariance (MANCOVA). RESULTS: Perceived vaccine efficacy was lowest for the next-week vaccine (η(2)(p) = .045). Self-efficacy was higher for the two-year vaccine than the next-week vaccine (η(2)(p) = .029). Perceived vaccine risk was higher for the next-week vaccine than for the one-year vaccine (η(2)(p) = .032). Vaccination willingness did not differ among experimental treatments. In addition, vaccine conspiracy beliefs were negatively related to perceived vaccine efficacy (η(2)(p) = .142), self-efficacy (η(2)(p) = .031), and vaccination willingness (η(2)(p) = .143) and positively related to perceived vaccine risk (η(2)(p) = .216). CONCLUSIONS: The rapid development of the COVID-19 vaccine may have heightened public concerns over efficacy, availability, and safety. However, the current findings showed a general willingness to take even the most rapidly developed vaccine. Nonetheless, there remains a need to communicate publicly and transparently about vaccine efficacy and safety and work to reduce vaccine conspiracy beliefs.
format Online
Article
Text
id pubmed-8590511
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-85905112021-11-15 Influence of rapid COVID-19 vaccine development on vaccine hesitancy Rosenthal, Sonny Cummings, Christopher L. Vaccine Article INTRODUCTION: In the race to deploy vaccines to prevent COVID-19, there is a need to understand factors influencing vaccine hesitancy. Secondary risk theory is a useful framework to explain this, accounting for concerns about vaccine efficacy and safety. METHODS: During the first week of July, 2020, participants (N = 216) evaluated one of three different hypothetical vaccine scenarios describing an FDA-approved vaccine becoming available “next week,” “in one year,” or “in two years.” Dependent variables were perceived vaccine efficacy, self-efficacy, perceived vaccine risk, and vaccination willingness. Covariates included vaccine conspiracy beliefs, science pessimism, media dependency, and perceived COVID-19 risk. Data analysis employed multiple analysis of covariance (MANCOVA). RESULTS: Perceived vaccine efficacy was lowest for the next-week vaccine (η(2)(p) = .045). Self-efficacy was higher for the two-year vaccine than the next-week vaccine (η(2)(p) = .029). Perceived vaccine risk was higher for the next-week vaccine than for the one-year vaccine (η(2)(p) = .032). Vaccination willingness did not differ among experimental treatments. In addition, vaccine conspiracy beliefs were negatively related to perceived vaccine efficacy (η(2)(p) = .142), self-efficacy (η(2)(p) = .031), and vaccination willingness (η(2)(p) = .143) and positively related to perceived vaccine risk (η(2)(p) = .216). CONCLUSIONS: The rapid development of the COVID-19 vaccine may have heightened public concerns over efficacy, availability, and safety. However, the current findings showed a general willingness to take even the most rapidly developed vaccine. Nonetheless, there remains a need to communicate publicly and transparently about vaccine efficacy and safety and work to reduce vaccine conspiracy beliefs. Elsevier Ltd. 2021-12-20 2021-11-13 /pmc/articles/PMC8590511/ /pubmed/34802786 http://dx.doi.org/10.1016/j.vaccine.2021.11.014 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Rosenthal, Sonny
Cummings, Christopher L.
Influence of rapid COVID-19 vaccine development on vaccine hesitancy
title Influence of rapid COVID-19 vaccine development on vaccine hesitancy
title_full Influence of rapid COVID-19 vaccine development on vaccine hesitancy
title_fullStr Influence of rapid COVID-19 vaccine development on vaccine hesitancy
title_full_unstemmed Influence of rapid COVID-19 vaccine development on vaccine hesitancy
title_short Influence of rapid COVID-19 vaccine development on vaccine hesitancy
title_sort influence of rapid covid-19 vaccine development on vaccine hesitancy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590511/
https://www.ncbi.nlm.nih.gov/pubmed/34802786
http://dx.doi.org/10.1016/j.vaccine.2021.11.014
work_keys_str_mv AT rosenthalsonny influenceofrapidcovid19vaccinedevelopmentonvaccinehesitancy
AT cummingschristopherl influenceofrapidcovid19vaccinedevelopmentonvaccinehesitancy